2019
Kardium® announces successful results from the GLOBAL-AF study (Financial Post)
10/08/2019
Global-AF study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe System.
Kardium® announces successful results from the GLOBAL-AF study
10/08/2019
October 8, 2019 9:00 AM Pacific Standard Time VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial […]
02/07/2019
Financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders.
02/07/2019
Kardium has raised an undisclosed amount in a new financing round.
01/24/2019
T. Rowe Price leads new round of financing together with new and existing investors January 24 2019 10:00 AM Pacific Standard Time VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. […]